NEW YORK—August 7, 2020—Fera is pleased to announce that, in addition to its already marketed 100-count bottle package size, it has now launched a 100-count unit dose blister package as well. The advantages of unit dose packaging include improved safety for hospital staff and patients and to help minimize inaccurate dosing. 

Fera believes the availability of this product will be important to hospital staff and their patients, especially in light of the recent preliminary finding that in patients hospitalized with COVID-19, the use of dexamethasone resulted in lower 28-day mortality among those receiving either ventilation or oxygen.1 


About Fera Pharmaceuticals

Fera Pharmaceuticals is a privately held company. The company goal is to realize opportunities via acquisitions, in-licensing, developing and marketing abbreviated new drug applications (ANDAs), new drug applications (NDAs), and 505(b)(2) NDA products. For more information visit www.ferapharma.com. 

REFERENCES 
1. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19— Preliminary Report. NEJM. July 17, 2020. 

Contact:
Susan McDougal
(516) 277-1449, contact@ferapharma.com